A multicenter randomized trial of Fludarabine and Mitoxantrone (FM) plus Rituximab versus CHOP plus Rituximab as first-line treatment in patients with follicular lymphoma (FL).

被引：0
|
作者：
Zinzani, PL [1 ]
机构：
[1] Univ Bologna, Inst Hematol & Med Oncol L & A Seranoli, I-40126 Bologna, Italy
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
344
引用
收藏
页码：93A / 93A
页数：1
相关论文
共 50 条
  • [31] The association of rituximab with CHOP in first-line treatment brings a significant benefit in the advanced stages of follicular lymphoma
    Choquet, Sylvain
    HEMATOLOGIE, 2006, 12 (01): : 13 - 14
  • [32] First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab plus /- nivolumab: An umbrella randomised phase 2 investigator-led study.
    Chong, Geoffrey
    Palmer, Jodie
    Barraclough, Allison
    Churilov, Leonid
    Keane, Colm
    Lee, Sze Ting
    Lee, Denise
    Ratnasingam, Sumita
    Smith, Charmaine
    Hawkes, Eliza Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Bendamustine plus rituximab versus chop plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas-interim results of a randomized phase III study of the stil (study group indolent lymphomas, germany)
    Rummel, M. J.
    ANNALS OF ONCOLOGY, 2008, 19 : 173 - 173
  • [34] Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi
    Margiotta-Casaluci, Gloria
    Bigliardi, Sara
    Cocito, Federica
    Meli, Erika
    Petrucci, Luigi
    Nicolosi, Maura
    Annibali, Ombretta
    Boccomini, Carola
    Bozzoli, Valentina
    Castellino, Alessia
    Cattina, Federica
    Cenfra, Natalia
    Ciavarella, Sabino
    Kovalchuk, Sofya
    Rotondo, Francesco
    Fama, Angelo
    Olivieri, Jacopo
    Zaja, Francesco
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [35] Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy
    Hornberger, John
    Chien, Rebecca
    Friedmann, Mark
    Han, Leona
    Shewade, Ashwini
    Satram-Hoang, Sacha
    Reyes, Carolina
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2371 - 2377
  • [36] Phase II study of short course CHOP-rituximab (R) followed by ibritumomab tiuxetan (IT) as first-line treatment for follicular lymphoma (FL)
    Jankowitz, R. C.
    Foon, K. A.
    DeMonaco, N. A.
    Osborn, J.
    Wu, M.
    Evans, T.
    Swerdlow, S. H.
    Joyce, J.
    Land, S.
    Jacobs, S. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
    Coiffier, Bertrand
    Osmanov, Evgenii A.
    Hong, Xiaonan
    Scheliga, Adriana
    Mayer, Jiri
    Offner, Fritz
    Rule, Simon
    Teixeira, Adriana
    Walewski, Jan
    de Vos, Sven
    Crump, Michael
    Shpilberg, Ofer
    Esseltine, Dixie-Lee
    Zhu, Eugene
    Enny, Christopher
    Theocharous, Panteli
    van de Velde, Helgi
    Elsayed, Yusri A.
    Zinzani, Pier Luigi
    LANCET ONCOLOGY, 2011, 12 (08): : 773 - 784
  • [38] CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma.
    Leonard, John
    Jung, Sin-Ho
    Johnson, Jeffrey L.
    Bartlett, Nancy
    Blum, Kristie A.
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)
    Leonard, John P.
    Jung, Sin-Ho
    Johnson, Jeffrey
    Pitcher, Brandelyn N.
    Bartlett, Nancy L.
    Blum, Kristie A.
    Czuczman, Myron
    Giguere, Jeffrey K.
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) : 3635 - +
  • [40] Safety of fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab in the treatment of stage TV indolent lymphoma.
    McLaughlin, P
    Hagemeister, FB
    Rodriguez, MA
    Sarris, AH
    Cabanillas, F
    Younes, A
    Dang, N
    Romaguera, JE
    BLOOD, 1999, 94 (10) : 264B - 264B
12345